GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » Return-on-Tangible-Asset
中文

BioPlus Acquisition (BioPlus Acquisition) Return-on-Tangible-Asset

: 2.62% (As of Jun. 2023)
View and export this data going back to 2022. Start your Free Trial

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BioPlus Acquisition's annualized Net Income for the quarter that ended in Jun. 2023 was $4.96 Mil. BioPlus Acquisition's average total tangible assets for the quarter that ended in Jun. 2023 was $189.73 Mil. Therefore, BioPlus Acquisition's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 was 2.62%.

The historical rank and industry rank for BioPlus Acquisition's Return-on-Tangible-Asset or its related term are showing as below:

BIOS' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.84   Med: 0.84   Max: 2.66
Current: 2.66

During the past 2 years, BioPlus Acquisition's highest Return-on-Tangible-Asset was 2.66%. The lowest was 0.84%. And the median was 0.84%.

BIOS's Return-on-Tangible-Asset is not ranked
in the Diversified Financial Services industry.
Industry Median: -0.33 vs BIOS: 2.66

BioPlus Acquisition Return-on-Tangible-Asset Historical Data

The historical data trend for BioPlus Acquisition's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPlus Acquisition Annual Data
Trend Dec21 Dec22
Return-on-Tangible-Asset
- 0.84

BioPlus Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 1.12 2.65 3.88 2.62

Competitive Comparison

For the Shell Companies subindustry, BioPlus Acquisition's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPlus Acquisition Return-on-Tangible-Asset Distribution

For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where BioPlus Acquisition's Return-on-Tangible-Asset falls into.



BioPlus Acquisition Return-on-Tangible-Asset Calculation

BioPlus Acquisition's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=1.996/( (235.981+238.325)/ 2 )
=1.996/237.153
=0.84 %

BioPlus Acquisition's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=4.964/( (240.82+138.63)/ 2 )
=4.964/189.725
=2.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2023) net income data.


BioPlus Acquisition  (NAS:BIOS) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


BioPlus Acquisition Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of BioPlus Acquisition's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPlus Acquisition (BioPlus Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
260 Madison Avenue, Suite 800, New York, NY, USA, 10026
Website
BioPlus Acquisition Corp is a blank check company.
Executives
Steven C. Fletcher 10 percent owner C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807
Explorer Parent Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Founder Holdings Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Alex Serge Vieux 10 percent owner C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749
Bioplus Sponsor Llc 10 percent owner 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Louis G Lange director 3172 PORTER DRIVE, PALO ALTO CA 94034
Ross Haghighat director, officer: CEO and CFO C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Ronald W Eastman director 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Shawn Cross director 1825 K STREET SUITE 510, WASHINGTON DC 20006
Jonathan Rigby director, officer: Chief Business Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Glen Giovannetti director UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000